[1] |
DENG Qiling, SONG Di, XI Kexin, XIE Xiaoting, WU Xiaoyan, ZHAO Wei.
Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients
[J]. China Oncology, 2025, 35(4): 355-364.
|
[2] |
LI Bin, TAO Zhonghua, HU Xichun.
Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
[J]. China Oncology, 2025, 35(3): 273-282.
|
[3] |
ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan.
Research status and prospects of treatment for malignant pleural mesothelioma
[J]. China Oncology, 2025, 35(3): 326-332.
|
[4] |
AN Tianqi, TIAN Jianhui, ZHOU Yiyang, LUO Bin, QUE Zujun, LIU Yao, YU Pan, ZHAO Ruihua, YANG Yun.
Research progress on treatment of pleural effusion related to immune checkpoint inhibitors
[J]. China Oncology, 2025, 35(3): 333-338.
|
[5] |
LIN Jialin, WANG Wenna, XU Binghe.
Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
[J]. China Oncology, 2025, 35(2): 154-166.
|
[6] |
WU Song, YUAN Yang, JIANG Zefei.
Important clinical studies that changed the clinical practice of advanced breast cancer in 2024
[J]. China Oncology, 2025, 35(2): 186-194.
|
[7] |
ZENG Cheng, WANG Yuanyi, WANG Jiani, MA Fei.
Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
[J]. China Oncology, 2025, 35(2): 195-204.
|
[8] |
GENG Qianqian, YANG Aimin.
Progress and prospect on treatment for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 30-39.
|
[9] |
LI Ruping, YANG Hui.
Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 40-48.
|
[10] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[11] |
FENG Xinying, WANG Bing, LIU Peifeng.
Innovations and challenges in intraperitoneal chemotherapy for peritoneal metastatic carcinoma
[J]. China Oncology, 2024, 34(9): 827-837.
|
[12] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[13] |
LIANG Yingyun, CHEN Jianhua.
Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors
[J]. China Oncology, 2024, 34(7): 686-694.
|
[14] |
HUANG Sijie, KANG Xun, LI Wenbin.
Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis
[J]. China Oncology, 2024, 34(7): 695-701.
|
[15] |
XU Yuchen, ZHANG Jian, WANG Yan, LIN Jinyi, ZHOU Yuhong, CHENG Leilei, GE Junbo.
Therapeutic effects of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis
[J]. China Oncology, 2024, 34(4): 400-408.
|